APLS icon

APLS

Lightning icon

21.98 USD

+6.77%

Today

-1.47%

1D

Last seen at Tue, 24 Feb 2026 23:39:00 GMT+3

Market is closed

Sun

Closed

Mon

4:30 PM ~ 10:59 PM

Tue

4:30 PM ~ 10:59 PM

Wed

4:30 PM ~ 10:59 PM

Thu

4:30 PM ~ 10:59 PM

Fri

4:30 PM ~ 10:59 PM

Sat

Closed

1D
5D
1M
3M
1Y
MAX

Performance

1 Day

- 1.47 %

1 Week

+ 2.12 %

1 Month

+ 8.74 %

3 Month

+ 13.77 %

6 Month

- 16.67 %

1 Year

- 21.90 %

Information

Name

Apellis Pharmaceuticals Inc Leveraged

Currency

USD

Standard Leverage

1X

Lightning Icon

Enhanced Leverage

3X

Lightning Icon

Overnight Fees Buy

-0.0191%

Overnight Fees Sell

0.0024%

Market Cap

3.18B

Avg Daily Volume

2.43M

52 Week High

35.57 USD

52 Week Low

16.1 USD

Trading Hours

See hours

Overnight Fees Calculator

ExposureUnits
USD
Daily Overnight Fee %Daily Overnight Fee $
BUYS-0.01910%$(0.191)
SELLS0.00240%$0.024

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Top News

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

tradingview.com

17h ago

No Image

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

tradingview.com

1d ago

No Image

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

tradingview.com

5d ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.